ApaTech Ltd Announces Appointment Of Simon Cartmell As Chief Executive Officer
10/19/2005 5:11:01 PM
ApaTech™ Limited, a private orthopaedics company specialising in synthetic bone graft substitutes, announced today the appointment of Simon Cartmell as Chief Executive Officer. Simon Cartmell has 23 years pharmaceutical, healthcare and biotechnology industry experience. He spent 17 years at GlaxoWellcome in a number of UK and global roles, including Therapy Area Director, Infectious Diseases and Hepatitis, with international research, development and commercial responsibility for this £1.8 billion business. Simon joined Vernalis plc (formerly Vanguard Medica plc) as Chief Operating Officer in 1998 before joining the main board of Celltech plc as Chief Executive Officer for Celltech Pharmaceuticals in mid 2000. In this role he was responsible for the performance and development of the global pharmaceuticals business, including supply operations. More recently Simon has been interim CEO of Entomed sa, a Strasbourg based, early stage biotech, where he remains a Non Executive Director. He is also Non Executive Chairman of Curidium Ltd.
comments powered by